Organogenesis Holdings Inc (ORGO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Organogenesis Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.30 $ — 2% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% -22.6%
- EBIT growth 10Y > 5% 86.0%
- Exp. EBIT growth 3Y > 5% -22.6%
- Net debt < 4x EBIT 0.7x
- EBIT positive, 10Y straight 6
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% 9.4%
- ROCE > 15% 11.2%
- Expected return > 10% -29.0%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
7 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 7.7% failed
- More than 10% revenue growth is expected for the coming year 19.4% passed
- Share count grows by less than 3% a year -0.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 12.5% failed
- Gross margin at 40% or higher and without meaningful erosion 75.6% passed
- Goodwill from acquisitions does not grow faster than revenue 4.8% passed
- Net debt below twice EBITDA 0.5 x EBITDA passed
- Operating cash flow covers the profits of the last three years -8 m failed
- Return on capital at 15% or higher, or up versus two years ago 11.2% passed
- Insiders hold at least 10% or are net buyers 47.5% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 30.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.82 | -0.90 – -0.74 | 283 | -293.5% | 2 |
| 12/31/2027 | -0.28 | -0.32 – -0.23 | 338 | 66.5% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.35 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.06 | – | 127 | 27.10 | 6.10 | 11 | 8 |
| 2025: Q1 | -0.15 | – | 87 | -21.20 | -21.70 | -20 | -24 |
| 2025: Q2 | -0.07 | – | 101 | -22.60 | -9.30 | -33 | -37 |
| 2025: Q3 | 0.16 | 79.00 | 151 | 30.70 | 14.30 | 3 | 1 |
| 2025: Q4 | 0.33 | 469.30 | 225 | 77.70 | 19.40 | 39 | 35 |
| 2026: Q1 | -0.44 | – | 37 | -57.10 | -150.90 | 21 | 18 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | 0 | 0 | -0.02 | -1 | 300 | 311 |
| 2017 | 0 | -5 | -2 | -0.03 | -1 | 298 | 313 |
| 2018 | 193 | -52 | -65 | -0.94 | -61 | 47 | 164 |
| 2019 | 261 | -30 | -39 | -0.42 | -34 | 56 | 221 |
| 2020 | 338 | 27 | 17 | 0.15 | 5 | 142 | 290 |
| 2021 | 467 | 72 | 94 | 0.70 | 62 | 241 | 443 |
| 2022 | 451 | 22 | 16 | 0.12 | 25 | 266 | 449 |
| 2023 | 433 | 13 | 5 | 0.04 | 31 | 279 | 460 |
| 2024 | 482 | -1 | 1 | 0.01 | 14 | 385 | 498 |
| 2025 | 563 | 56 | 37 | 0.28 | -10 | 434 | 599 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Organogenesis Holdings Inc. , a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
| Employees | 854 |
|---|---|
| Headquarters | Canton, MA |
| Address | 85 Dan Road, 02021 Canton, United States |
| Phone | 781 575 0775 |
| Website | organogenesis.com |
| IPO Date | 5. Jan 2017 |
| ISIN | US68621F1021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gary S. Gillheeney Sr. | President, CEO, Chair of the Board | 1955 |
| David C. Francisco | Chief Financial Officer | 1966 |
| Patrick Bilbo | Chief Operating Officer | 1962 |
| Lori H. Freedman B.A., Esq., J.D. | Chief Administrative & Legal Officer | 1967 |
| Brian Grow | Chief Commercial Officer | 1976 |
| Patrick McGuire | Chief Accounting Officer | 1986 |
| Robert Cavorsi | Chief Business Officer | 1979 |
| William R. Kolb CPA | Secretary | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.